MedTrace Logo

Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli

NCT02537847 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2015-09-02

No results posted yet for this study

Summary

The aim of the investigators' study was to evaluate oral and non carbapenem antimicrobial agents which can be used in outpatient for the treatment of non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli. This study was conducted to compare the clinical and bacteriological outcomes of patients with non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli who were treated with intravenous (IV) carbapenems followed by oral sitafloxacin or IV ertapenem.

Conditions

  • Infection Due to Escherichia Coli
  • Acute Pyelonephritis

Interventions

DRUG

Sitafloxacin

The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.

DRUG

Ertapenem

Control group will be given ertapenem only for 10 days.

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Sasisopin Kiertiburanakul · Ramathibodi Hospital Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-09-30
Completion
2016-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537847 on ClinicalTrials.gov